Literature DB >> 22812604

Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism.

P Bucciarelli1, S M Passamonti, E Biguzzi, F Gianniello, F Franchi, P M Mannucci, I Martinelli.   

Abstract

BACKGROUND: Inherited deficiencies of antithrombin (AT), protein C (PC) and protein S (PS) are risk factors for venous thromboembolism (VTE). They are usually defined by laboratory cut-offs (in our setting 81, 70 and 63 IU dL(-1), respectively), which give only a rough idea of the VTE risk associated with plasma levels of these proteins.
OBJECTIVES: We investigated whether the risk of VTE associated with the plasma deficiencies of AT, PC or PS has a dose-response effect, and whether low borderline levels of these proteins are associated with an increased risk of VTE, both in the whole study population and separately in carriers of either factor V Leiden or G20210A prothrombin gene mutation. PATIENTS/
METHODS: A case-control study of 1401 patients with a first objectively-documented VTE and 1847 healthy controls has been carried out.
RESULTS: A dose-response effect on the VTE risk was observed for all the three anticoagulant proteins. Compared with individuals with AT, PC or PS levels > 100 IU/dL, the adjusted odds ratio (95% CI) of VTE was 2.00 (1.44-2.78) for AT levels between 76 and 85 IUdL(-1) , 2.21 (1.54-3.18) and 1.84 (1.31-2.59) for PC and PS levels between 61 and 75 IUdL(-1) . The risk of unprovoked VTE in factor V Leiden or prothrombin G20210A carriers appears 2 to 3-fold increased when levels of AT or PS are low borderline.
CONCLUSIONS: Low borderline plasma levels of AT, PC and PS are associated with a 2-fold increased risk of VTE and should be considered in the assessment of the individual VTE risk.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812604     DOI: 10.1111/j.1538-7836.2012.04858.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Haemostatic and fibrinolytic changes in obese subjects undergoing bariatric surgery: the effect of different surgical procedures.

Authors:  Roberta Lupoli; Marco Milone; Alessandro Di Minno; Paola Maietta; Pasquale Ambrosino; Mario Musella; Matteo N D Di Minno
Journal:  Blood Transfus       Date:  2014-12-16       Impact factor: 3.443

2.  MPI-CDG with transient hypoglycosylation and antithrombin deficiency.

Authors:  María Eugenia de la Morena-Barrio; Ewa Wypasek; Danuta Owczarek; Antonia Miñano; Vicente Vicente; Javier Corral; Anetta Undas
Journal:  Haematologica       Date:  2018-12-13       Impact factor: 9.941

Review 3.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

4.  Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency.

Authors:  Wei Zeng; Bei Hu; Liang Tang; Yan-Yan You; Mara Toderici; Maria Eugenia de la Morena-Barrio; Javier Corral; Yu Hu
Journal:  Oncotarget       Date:  2017-09-28

5.  Association of SERPINC1 Gene Polymorphism (rs2227589) With Pulmonary Embolism Risk in a Chinese Population.

Authors:  Yongjian Yue; Qing Sun; Lu Xiao; Shengguo Liu; Qijun Huang; Minlian Wang; Mei Huo; Mo Yang; Yingyun Fu
Journal:  Front Genet       Date:  2019-09-13       Impact factor: 4.599

6.  Patients with SERPINC1 rs2227589 polymorphism found to have multiple cerebral venous sinus thromboses despite a normal antithrombin level: A case report.

Authors:  Feng Liao; Jun-Ling Zeng; Jian-Gang Pan; Jing Ma; Zhi-Jian Zhang; Zhi-Jun Lin; Li-Feng Lin; Yu-Sen Chen; Xiao-Tang Ma
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

7.  Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency.

Authors:  Mara Toderici; María Eugenia de la Morena-Barrio; José Padilla; Antonia Miñano; Ana Isabel Antón; Juan Antonio Iniesta; María Teresa Herranz; Nuria Fernández; Vicente Vicente; Javier Corral
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.